{"groups":[{"description":"Three drug regimen using busulfan, and melphalan, and alemtuzumab.\n\nBusulfan, and melphalan, and alemtuzumab: intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).\n\nIntravenous melphalan 100 mg/m2 on day -3.\n\nIntravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1.","id":"FG000","title":"Busulfan, and Melphalan, and Alemtuzumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}